In the US pharmaceutical industry, there were 174 M&A deals announced in Q3 2023, worth a total value of $16.8bn, according to GlobalData’s Deals Database. The $7.3bn acquisition of Reata Pharmaceuticals by Biogen was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q3 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, M&A activity in the US decreased by 55% in Q3 2023 compared with the previous quarter’s total of $37.2bn and fell by 27% as compared to Q3 2022. Related deal volume decreased by 30% in Q3 2023 versus the previous quarter and was 0.6% lower than in Q3 2022.
The top-ranked legal advisorss supporting these M&A deals in the US Q3 2023 were Goodwin Procter; Kirkland & Ellis; Gibson, Dunn & Crutcher with 18, 17, 16 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2023 – Thematic Intelligence, buy the report here.